Research Paper Volume 15, Issue 19 pp 10453—10472
An immune signature to predict the prognosis of ATRX-wildtype glioma patients and guide immune checkpoint blockade therapy
Figure 9. Expression of HOXA5, PTPN2, WT1, HOXD10, POSTN, ADAMDEC1 and MYBPH in ATRX-wt glioma tissues. ATRX-wt patients were divided into long-term and short-term survival groups based on a cut-off of 15 months. (A) Immunohistochemistry scores for HOXA5, PTPN2, WT1, HOXD10, POSTN, ADAMDEC1 and MYBPH in ATRX-wt glioma tissues. (B) Representative plots of HOXA5, PTPN2, WT1, HOXD10, POSTN, ADAMDEC1 and MYBPH expression in ATRX-wt glioma tissues from the long- and short-term survival groups. (C) Prognostic value of HOXA5, PTPN2, WT1, HOXD10, POSTN, ADAMDEC1 and MYBPH1 in distinguishing ATRX-wt glioma patients with long- and short-term survival.